{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:46:51Z","timestamp":1777423611270,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.vaccine.2021.10.019","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T20:44:31Z","timestamp":1634589871000},"page":"7066-7073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Reactogenicity within 2\u00a0weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-8937","authenticated-orcid":false,"given":"Johanna","family":"Chapin-Bardales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-8402","authenticated-orcid":false,"given":"Tanya","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julianne","family":"Gee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Shay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Baggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-2115","authenticated-orcid":false,"given":"Bicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Licata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom T.","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"50","key":"10.1016\/j.vaccine.2021.10.019_b0005","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5152","key":"10.1016\/j.vaccine.2021.10.019_b0010","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"27","key":"10.1016\/j.vaccine.2021.10.019_b0015","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.019_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.10.019_b0025","unstructured":"Centers for Disease Control and Prevention. V-safe active surveillance for COVID-19 vaccine safety protocol. January, 28 2021, version 2. https:\/\/www.cdc.gov\/vaccinesafety\/pdf\/V-safe-Protocol-508.pdf; [accessed April 14, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.019_b0030","doi-asserted-by":"crossref","unstructured":"Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First Month of COVID-19 Vaccine Safety Monitoring \u2014 United States, December 14, 2020\u2013January 13, 2021. MMWR Morbidity and mortality weekly report February 2021; 26; 70(8): 283-8. doi:10.15585\/mmwr.mm7008e3","DOI":"10.15585\/mmwr.mm7008e3"},{"issue":"21","key":"10.1016\/j.vaccine.2021.10.019_b0035","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines","volume":"325","author":"Chapin-Bardales","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.10.019_b0040","unstructured":"Advisory Council on Immunization Practices. Live Meeting Archives: January 27, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/live-mtg-2021-01-27.html; [accessed May 10, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.019_b0045","unstructured":"Weise E. 'COVID arm' rash seen after Moderna vaccine annoying but harmless, doctors say. USA Today. January 27, 2021. https:\/\/www.usatoday.com\/story\/news\/health\/2021\/01\/27\/covid-arm-moderna-vaccine-rash-harmless-side-effect-doctors-say\/4277725001\/; [accessed April 14, 2021]."},{"issue":"13","key":"10.1016\/j.vaccine.2021.10.019_b0050","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMc2102131","article-title":"Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2","volume":"384","author":"Blumenthal","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2021.10.019_b0055","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1056\/NEJMc2108620","article-title":"Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color","volume":"385","author":"Samarakoon","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.10.019_b0060","unstructured":"Cassell DL. The Basics of the PRX Functions. SAS Global Forum 2007. Paper 223-2007. https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/forum2007\/223-2007.pdf; [accessed April 14, 2021]."},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.019_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"npj Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2021.10.019_b0070","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.mad.2005.03.008","article-title":"The inflammatory response to vaccination is altered in the elderly","volume":"126","author":"El Yousfi","year":"2005","journal-title":"Mech Ageing Dev."},{"issue":"25","key":"10.1016\/j.vaccine.2021.10.019_b0075","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2021.10.019_b0080","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.vaccine.2021.10.019_b0085","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1\u201330, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"28","key":"10.1016\/j.vaccine.2021.10.019_b0090","doi-asserted-by":"crossref","first-page":"923","DOI":"10.15585\/mmwr.mm6928e1","article-title":"Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020","volume":"69","author":"Wortham","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"10.1016\/j.vaccine.2021.10.019_b0095","doi-asserted-by":"crossref","first-page":"858","DOI":"10.15585\/mmwr.mm7023e2","article-title":"Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021","volume":"70","author":"Christie","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2021.10.019_b0100","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","article-title":"Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older","volume":"39","author":"Ackerson","year":"2021","journal-title":"Vaccine."},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.019_b0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2021.10.019_b0110","article-title":"Delayed Large Local Reactions to mRNA Vaccines","volume":"384","author":"Baeck","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.019_b0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2021.10.019_b0120","unstructured":"CDC COVID-19 Data Tracker. Trends in Number of COVID-19 Vaccinations in the US. April 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccination-trends; [accessed May 10, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.019_b0125","unstructured":"Centers for Disease Control and Prevention. Vaccination Demographic Trends. 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccination-demographics-trends; [accessed July 7, 2021]."},{"issue":"11","key":"10.1016\/j.vaccine.2021.10.019_b0130","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US\u2014December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.10.019_b0135","unstructured":"Centers for Disease Control and Prevention. COVID-19 Vaccination: Answering Patients\u2019 Questions. 2020. https:\/\/www.cdc.gov\/vaccines\/covid-19\/hcp\/answering-questions.html; [accessed May 17, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.019_b0140","unstructured":"Centers for Disease Control and Prevention. Possible Side Effects After Getting a COVID-19 Vaccine. 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/expect\/after.html; [accessed May 17, 2021]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:04:35Z","timestamp":1759403075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21013396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0264410X21013396"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reactogenicity within 2\u00a0weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}